C Diff Diagnosis

This study shows the possibility of rapid discrimination of relevant C. difficile ribotypes by using MALDI-TOF MS. This methodology reduces the time, costs and laboriousness of current reference methods.

This rapid review identified and summarised evidence of the accuracy of new diagnostic tests for Clostridioides difficile (C. difficile).

The laboratory diagnosis of iClostridioides difficile/i infection (CDI) is controversial. Nucleic acid amplification tests (NAAT) and toxin enzyme immunoassays (EIA) are most widely used, often in combination. However, the interpretation of a positive NAAT and negative toxin immunoassay (NAAT+/E …

The German firm said that it plans to launch its AltoStar Parvovirus B19 PCR Kit 1.5 in January and other unspecified tests through spring of 2025.

spaniClostridioides difficile/i species lacking toxin genes (non-toxigenic iC. difficile/i or NTCD) may confer protection against CDI. However, current diagnostic tests detect either toxin proteins or toxin genes and cannot detect NTCD. This study developed a molecular testing method that unique/span …

ClinicalTrials.gov Identifier: NCT04078594.

Reimbursement for molecular syndromic panel testing for UTI may continue to face uncertainty.

TEHRAN (ANA)- Iranian researchers from University of Tehran succeeded in developing and designing an electrochemical genosensor to identify different strains of the C. difficile bacteria with high sensitivity and accuracy.

The gut microbiota might perhaps one day become a routine tool for the early diagnosis of many diseases and to guide treatment, but at present there

Researchers found that removing Clostridioides difficile from gastrointestinal pathogen panels reduced unnecessary treatment without causing delays in diagnosis.

Diagnosis of Clostridioides difficile infection (CDI) remains challenging as it involves in the first instance recognition (clinical awareness) of the patients' symptoms for clinical suspicion of CDI to warrant testing, and secondly, different laboratory tests have been described for CDI. Due …

Investigators were seeking clarification on optimal sequencing of the immune checkpoint inhibitor atezolizumab following treatment failure and disease progression after receipt of nivolumab and pembrolizumab.

Current guidelines recommend a two-step algorithm rather than relying solely on a single test for diagnosing Clostridioides difficile infection. This algorithm starts with enzyme immunoassay (EIA) for detecting glutamate dehydrogenase (GDH) and toxins A/B, followed by nucleic acid amplificati …

The detection of C. difficile in a much high number of these samples by shotgun metagenomics, albeit at low levels of relative abundance, suggests that neither of these culture protocols is sensitive when levels of abundance are low.

Clostridioides difficile became one of the main causes of nosocomial infections in all clinical settings worldwide, especially among patients undergoing antibiotic therapy. The incidence and severity of C. difficile infections, from mild diarrhea to life-threatening pseudomembranous co …

Paul Feuerstadt, MD, FACG, AGAF, discusses how testing for Clostridioides difficile is recommended for hospitalized patients or outpatients with new-onset, unexplained diarrhea who have risk factors such as recent antibiotic use, hospitalization, or older age, and how empiric treatment should be initiated while awaiting test results if there is high clinical suspension.

Removing C. difficile from the GIPP resulted in effective diagnostic and antimicrobial stewardship without resulting in delayed diagnoses.

An Unusual Cause of Diarrhea and Hematochezia

Target product profiles (TPPs) for new medical tests provide test developers with performance benchmarks and technical requirements for new tests. Early economic evaluation has already been used to identify acceptable ranges for certain performance requirements for new tests. Currently, however, ear …

The BHAT improved clinicians' comfort level discussing patient's bowel habits. Health care providers found the BHAT useful and related to their work. This tool shows promise in improving providers' comfort discussing bowel habits and diagnosing Clostridioides difficile in a timely manner.

Acurx is proud to sponsor this inaugural Scientific Symposium of the Peggy Lillis Foundation (PLF) for C. Diff Education & Advocacy An update of ibezapolstat...

New Test Detects 26 Bacteria, Viruses, and Parasites in a Single, Simple Stool Swab LAKE FOREST, Calif., Nov. 14, 2024 /PRNewswire-PRWeb/ -- EmeritusDX, a rapidly growing diagnostics and information company, today...

MGPP testing is most useful when administered as an outpatient and of little benefit for inpatients with hospital-onset diarrhea. Since MGPP is sensitive and does not distinguish between colonization and causes of diarrhea, caution is needed in interpretation of results, especially for toxin-negativ …

The diagnosis, pharmacologic management, and surgical options for Clostridioides difficile infection (CDI) are rapidly evolving, which presents a challenge for the busy surgeon to remain up to date on the latest clinical guidelines. This review provides an evidence-based practical guide for CDI mana …

Healthcare

The certification is for products used in hematology instruments manufactured globally, including instruments from Abbott, Beckman Coulter, and Siemens Healthineers.

The global antimicrobial resistance diagnostics market was valued at USD 4.4 billion in 2023 and is estimated to grow at a CAGR of over 6.3% from 2024 to 2032 driven by increasing incidence of drug-resistant infection.

Rapid diagnostics enhance patient outcomes by enabling prompt, targeted treatments, reducing inappropriate antibiotic use, and combating antimicrobial resistance through informed clinical decisions and stewardship programs.

Fecal testing is still very relevant in the practice of gastroenterology and deserves introduction of advanced microbiological and biochemical tests.